Cargando…

Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities

BACKGROUND: Vibration-controlled transient elastography (VCTE) is proposed as a second step of examination to assess liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) after triaging by the fibrosis-4 (FIB-4) index. Recently, VCTE-based scoring systems, including FibroScan-AST...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miura, Kouichi, Maeda, Hiroshi, Morimoto, Naoki, Watanabe, Shunji, Tsukui, Mamiko, Takaoka, Yoshinari, Nomoto, Hiroaki, Goka, Rie, Kotani, Kazuhiko, Yamamoto, Hironori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157683/ https://www.ncbi.nlm.nih.gov/pubmed/35720167 http://dx.doi.org/10.4291/wjgp.v13.i3.96

Ejemplares similares

Acute Liver Failure Caused by the Transmission of Hepatitis B Virus from the Spouse after 38 Years of Marriage
por: Sato, Naoto, et al.
Publicado: (2019)

Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases under Receiving of Tyrosine Kinase Inhibitors
por: Maeda, Hiroshi, et al.
Publicado: (2022)

Oxidized High-Density Lipoprotein Shows a Stepwise Increase as Fibrosis Progresses in Patients with Nonalcoholic Fatty Liver Disease
por: Miura, Kouichi, et al.
Publicado: (2021)

Usefulness of Gd-EOB-DTPA-enhanced MRI for evaluating the potential for early development of hepatocellular carcinoma after HCV eradication by direct-acting antiviral treatment
por: Morimoto, Naoki, et al.
Publicado: (2019)

Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high‐fat diet
por: Miura, Kouichi, et al.
Publicado: (2019)

A 79-year-old Woman with Acute Hepatitis B Caused by the Infection of Subgenotype D1 Hepatitis B Virus in Japan: A Case Study
por: Hashimoto, Kosei, et al.
Publicado: (2018)

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease
por: Shrestha, Rupesh, et al.
Publicado: (2021)

The association of weight gain with nonalcoholic fatty liver disease and fibrosis detected by FibroScan in the United States
por: Wijarnpreecha, Karn, et al.
Publicado: (2022)

Diagnostic Accuracy of FibroScan and Factors Affecting Measurements
por: Oeda, Satoshi, et al.
Publicado: (2020)

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
por: Friedrich-Rust, Mireen, et al.
Publicado: (2010)

Efficacy and safety of glecaprevir and pibrentasvir combination therapy in old-aged patients with chronic hepatitis C virus infection
por: Watanabe, Shunji, et al.
Publicado: (2020)

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children
por: Chaidez, Alexander, et al.
Publicado: (2022)

Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease
por: Li, Qiang, et al.
Publicado: (2020)

Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease
por: Yang, Xinyu, et al.
Publicado: (2021)

Prospective Comparison of Transient Elastography Using Two Different Devices: Performance of FibroScan and FibroTouch
por: Serra, Joao Tiago, et al.
Publicado: (2020)

Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study
por: Nomoto, Hiroaki, et al.
Publicado: (2020)

Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease
por: Eris, Tansu, et al.
Publicado: (2023)

Laboratory Tests, Liver Vessels Color Doppler Sonography, and FibroScan Findings in Patients with Nonalcoholic Fatty Liver Disease: An Observation Study
por: Alizadeh, Ahmad, et al.
Publicado: (2018)

The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease
por: Wilder, Julius, et al.
Publicado: (2014)

Points to Be Considered When Applying FibroScan S Probe in Children With Biliary Atresia
por: Kim, Seung, et al.
Publicado: (2014)

A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis
por: Jun, Baek Gyu, et al.
Publicado: (2017)

Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!
por: Berger, Arthur, et al.
Publicado: (2019)

The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
por: Yilmaz, Yusuf, et al.
Publicado: (2023)

Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators
por: Chan, Yin, et al.
Publicado: (2017)

No Regional Disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 Infection in Tochigi Prefecture and Its Vicinity
por: Hirosawa, Takuya, et al.
Publicado: (2018)

Correlates of hepatic stiffness by FibroScan(©) in a multicentric Italian cohort of HIV-infected patients
por: Tarquini, P, et al.
Publicado: (2010)

Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis
por: Wong, Stephanie, et al.
Publicado: (2017)

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B
por: He, Tingshan, et al.
Publicado: (2020)

Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients
por: Durango, Esteban, et al.
Publicado: (2013)

Liver Biopsy and FibroScan to Detect Early Histopathological Changes in Chronic HBV Patients Not Candidate for Treatment
por: Maklad, Sahar, et al.
Publicado: (2014)

Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan)
por: Hussain, Azhar, et al.
Publicado: (2019)

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
por: Sanyal, Arun J., et al.
Publicado: (2023)

Diagnostic accuracy of transient elastography (FibroScan) in detection of esophageal varices in patients with cirrhosis: A meta-analysis
por: Pu, Ke, et al.
Publicado: (2017)

Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement
por: Huang, Zhimin, et al.
Publicado: (2022)

Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease
por: Ng, Ying Zhuang, et al.
Publicado: (2021)

Clinical relevance of lipid panel and aminotransferases in the context of hepatic steatosis and fibrosis as measured by transient elastography (FibroScan®)
por: Chi-Cervera, Luis Alberto, et al.
Publicado: (2021)

Effect of FibroScan test in antiviral therapy for HBV-infected patients with ALT <2 upper limit of normal
por: Han, Xian-Zhi, et al.
Publicado: (2020)

Serum uric acid to creatinine ratio is associated with higher prevalence of NAFLD detected by FibroScan in the United States
por: Wang, Rusha, et al.
Publicado: (2022)

2209. Discordance Between FibroSure and FibroScan Results in Hepatitis C and Human Immunodeficiency Virus Co-infected Patients Prior to Treatment for Hepatitis C Virus Infection
por: Tiyouh, Melissa, et al.
Publicado: (2018)

Feasibility study and reference values of FibroScan 502 with M probe in healthy preschool children aged 5 years
por: Zeng, Jing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k5cijpplka1m1an5io042jtfu5